Neovacs and Centurion Pharma continue their collaboration in Lupus based on the results of the Phase IIb trial with IFNalpha ...
11 Décembre 2018 - 7:30AM
PRESS RELEASE
· PRESS RELEASE · PRESS RELEASE
Neovacs and
Centurion Pharma continue their collaboration in
Lupus
based on the results of the Phase IIb trial with
IFNalpha Kinoid
Paris and Boston,
December 11th 2018 - 7:30
am CET - Neovacs (Euronext Growth Paris: ALNEV), leader in the
field of active immune therapy for the treatment of
autoimmune-diseases, confirms the decision of Centurion Pharma to
pursue the partnership on the basis of the licensing agreement
signed between both companies in July 2017 for the development of
IFNalpha Kinoid in the indication Lupus (SLE). This is the
consequence of the analysis and validation by Centurion Pharma of
the results of the Phase IIb trial in this indication. Through this
contract Centurion Pharma has acquired an exclusive commercial
license for Turkey.
"The introduction
of IFNalpha Kinoid
for the treatment of Lupus in Turkey is part of our corporate
strategy to bring innovative treatment in the field of healthcare
into our country, which will reach 90 mio inhabitants in a few
years" declares Ersin M. Erfa, CEO of Centurion Pharma.
In this context, Centurion Pharma
could take specific initiatives towards health authorities in
Turkey. According to Turkish regulations an import and marketing
authorization on a name patient basis could be obtained, once such
marketing authorization is obtained in another country.
A status of ODD (Orphan Drug
Designation) is actually being prepared for filing in South Korea.
The approval of such a status would allow an accelerated submission
for registration.
On a global basis Neovacs is
actually preparing the protocol of the Phase III trial and working
on the strategies for registration of IFNalpha Kinoid.
The agreement with Centurion
Pharma has foreseen a global payment of 6 mio € to Neovacs. A first
payment has been made at the signature of this exclusive license
agreement with Centurion Pharma in 2017. Further payments are
foreseen according to defined clinical and regulatory milestones.
Neovacs will also receive royalties based on net sales of
IFNalpha Kinoid in Turkey.
About Centurion
Pharma
Since 1979, Centurion Pharma has
been serving the Turkish market with therapeutic care products for
the treatment of specific and rare diseases encountered in Turkey
as well as biological, biotechnological and hospital products
through collaborations with leading pharmaceutics of the world.
Centurion Pharma head office is located in Istanbul and the Company
expanded its production activities in Ankara for biosimilars,
vaccines, orphan drugs and hospital generics. The R&D
activities are located at the Centurion Pharma production area with
a main focus on specific therapeutic areas. The company will expand
the business for neighborhood countries like Middle East, CIS,
Africa and Balkan countries after the start of local
production.
http://www.centurion.com.tr/
About
Neovacs
Listed on Euronext Growth since 2010, Neovacs is today a leading
biotechnology company focused on an active immunotherapy technology
platform (Kinoids) with applications in autoimmune and/or
inflammatory diseases. On the basis of the company's proprietary
technology for inducing a polyclonal immune response (covered by
four patent families that potentially run until 2032) Neovacs is
focusing its clinical development efforts on IFNalpha Kinoid,
an immunotherapy being developed for the indication of lupus,
dermatomyositis and also in preclinical trial for Type 1 diabetes.
Neovacs is also conducting preclinical development works on other
therapeutic vaccines in the fields of auto-immune diseases,
oncology and allergies. The goal of the Kinoid approach is to
enable patients to have access to safe treatments with efficacy
that is sustained in these life-long diseases. www.neovacs.fr
Contacts
NEOVACS -
Corporate Communication & Investor Relations
Charlène Masson
+33 1 53 10 93 00
cmasson@neovacs.com
NEWCAP-
Media
Annie-Florence Loyer
+33 1 44 71 00 12 / + 33 6 88 20 35 59
afloyer@newcap.fr
Léa Jacquin
+33 1 44 71 20 41 / +33 6 58 14 84 66
ljacquin@newcap.fr
Press release
This
announcement is distributed by West Corporation on behalf of West
Corporation clients.
The issuer of this announcement warrants that they are solely
responsible for the content, accuracy and originality of the
information contained therein.
Source: NEOVACS via Globenewswire
Neovacs (EU:ALNEV)
Graphique Historique de l'Action
De Avr 2024 à Mai 2024
Neovacs (EU:ALNEV)
Graphique Historique de l'Action
De Mai 2023 à Mai 2024